Previous 10 | Next 10 |
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors PR Newswire Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President ...
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Compan...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing PR Newswire EsoGuard demonstrated unprecedented early precancer de...
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PR Newswire Parties to implement a pilot program of the Veris Cancer Care Platform NEW ...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK , April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commer...
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK , April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention...
2024-03-28 10:01:50 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run John...
2024-03-27 15:12:10 ET PAVmed Inc. (PAVM) Q4 2023 Earnings Conference Call March 27, 2024 08:30 ET Company Participants Dennis McGrath - Executive Vice President & Chief Financial Officer Lishan Aklog - Chairman & Chief Executive Officer Conference Call...
2024-03-27 00:53:53 ET More on PAVmed Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha For further details see: PAVmed Non-GAAP EPS of -$1.33 ...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PR Newswire First patients enrolled on the Veris Cancer Care Platform NEW YORK , ...
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing PR Newswire Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June...